Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): April 30, 2020


Commission File No. 000-16929


Soligenix, Inc.

(Exact name of small business issuer as specified in its charter)


DELAWARE   41-1505029
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification Number)

29 Emmons Drive,

Suite B-10

Princeton, NJ





(Address of principal executive offices)   (Zip Code)


(609) 538-8200
(Issuer’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $.001 per share   SNGX   The Nasdaq Capital Market
Common Stock Purchase Warrants   SNGXW   The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company     


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    







Item 8.01.     Other Events.


On April 30, 2020, Soligenix, Inc. issued a press release announcing that continued treatment with SGX301 (synthetic hypericin) twice weekly for 12 weeks increased the positive response rate to 40% (p<0.0001 compared to placebo and p<0.0001 compared to 6-weeks treatment) in the open-label treatment cycle of its pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study for the treatment of early-stage cutaneous T-cell lymphoma. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.  


Item 9.01.     Financial Statements and Exhibits.


(d)      Exhibits.


Exhibit No.   Description
99.1   Press release of Soligenix, Inc. dated April 30, 2020.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Soligenix, Inc.  


April 30, 2020  By: /s/ Christopher J. Schaber 

Christopher J. Schaber, Ph.D.

President and Chief Executive Officer

(Principal Executive Officer)







Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Soligenix Charts.
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Soligenix Charts.